Oncologyassetlistforasco 15may2017

UK Oncology Assets ASCO Annual Meeting June 2017

Chicago, IL To connect with any of the companies listed here, please contact:

Kathryne.Kirk@mobile.trade.gov.uk or Torrey.Ah-Tye@mobile.trade.gov.uk

2

2017 Partnering Assets

Contents Cancer Research Technology (CRT)

3

Medical Research Council Technology (MRC-T)

4

Immunotherapy

5

T-Cell Therapies

6

Antibody Therapeutics

7

Small Molecule Inhibitors

9

Gene Therapy

10

Drug Discovery in Rare & Orphan Indications

11

Clinical Oncology: Medical Devices and Technology

13

3

2017 Partnering Assets

CANCER RESEARCH TECHNOLOGY Name SMALL MOLECULES CONTACT: ANDREA SCHIEVELLA, HEAD OF BUSINESS DEVELOPMENT

http://www.cancertechnology.co.uk/

BIOLOGICAL THERAPEUTICS CONTACT: ANDREA SCHIEVELLA, HEAD OF BUSINESS DEVELOPMENT

ENABLING TECHNOLOGY OPPORTUNITIES CONTACT: ANDREA SCHIEVELLA, HEAD OF BUSINESS DEVELOPMENT

MEDICAL DEVICES CONTACT: ANDREA SCHIEVELLA, HEAD OF BUSINESS DEVELOPMENT

DIAGNOSTICS OPPORTUNITIES CONTACT: ANDREA SCHIEVELLA, HEAD OF BUSINESS DEVELOPMENT

About Keywords: enzyme / checkpoint inhibitors, oncology targets, cancer targets, pre-clinical, drug discovery platforms, stem cells Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘the meeting point between academia and industry.’

Assets 1. Chk2 inhibitor program 2. First in class IKK alpha selective inhibitors 3. Inhibitors of autotoxin 4. Novel dual inhibitors of FLT3 & Aurora Kinases

1. CEA antibodies 2. vß6-binding peptides for tumor Keywords: antibodies, tumor targeting targeting 3. MUC1 peptides, trap therapy, angiogenesis, T- 4. S100A4 neutralizing antibody cell receptors 5. IGF2-Trap therapy 6. vß6 antagonistic antibodies Description: Part of Cancer Research 7. TACE antibody UK, CRT develops and commercializes 8. p53 TCR mimic antibody new discoveries in cancer research as 9. CLEC14a ‘the meeting point between academia 10. Jagged1 Monoclonal Antibody and industry.’

11. LMP2-TCR 12. CXCL12 13. CCR4 14. Anti-CD55 Antibodies Keywords: imaging agents, prostate cancer, glioma, tumor detection, radiolabelling, FRET- FILM, leukemia cell assay, kinase substrate identification

1. Optimam mammography image database and viewing software

Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘the meeting point between academia and industry.’

3. RALA

Keywords: biological fluid filtration, cancer diagnostics, high intensity focused ultrasound, sonic ablation

2. Imaging agent for prostate and glioma tumor detection

1. Biological fluid filtration device, for capture of material from biological fluids, such as tumor cells from urine, patent pending.

Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘the meeting point between academia and industry.’

Keywords: diagnostics, screening, breast cancer risk, imaging validation, ovarian cancer predictive, lung cancer, pancreatic cancer, prostate cancer Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘the meeting point between academia and industry.’

1. vß6 binding peptides for imaging 2. MCM Lung

4

2017 Partnering Assets

MRC TECHNOLOGY Name ONCOLOGY CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

About Keywords: immuno-oncology, immunology, oncology, antibodies, neoplasm, signaling molecule modulator, Millipore kinase panel, autophagy Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

CANCER DIAGNOSTICS CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

Keywords: cancer, oncology, kidney, renal cell carcinoma, tyrosine kinase inhibitors, diagnostic, gene profile, sunitinib, response

Assets 1. MNK Inhibitors for outlicensing 2. ULK Inhibitors for outlicensing 3. PAICS Inhibitors for outlicensing

Genetic markers for therapy in renal cell carcinoma (RCC) Provides stratification of renal cell carcinoma to improve patient outcome and therapy options.

Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

ONCOLOGY THERAPEUTICS CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

Keywords: cancer, oncology, therapeutic, pro-drug, therapeutic, palladium activated, endotoxaemia, ang2, angiopoietin, sepsis retinopathy, Src, abl, breast cancer, ovarian cancer Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

1. Targeting cancer therapeutics with palladium-activated compounds 2. Ang2 specific biotherapeutic 3. Specific Src inhibitor

5

2017 Partnering Assets

IMMUNOTHERAPY Name CANCER IMMUNOTHERAPY CONTACT: STEPHEN SHUTTLEWORTH, CHIEF SCIENTIFIC OFFICER

www.karustherapeutics.com/

ONCOLOGY, FIBROSIS & AUTOIMMUNE CONTACT: NICHOLAS ADAMS, CHIEF BUSINESS OFFICER

redxpharma.com

ONCOLYTIC IMMUNOTHERAPY CONTACT: JOHN BEADLE, CHIEF EXECUTIVE OFFICER

About

Assets

Keywords: Cancer, Targeted Therapy, Cancer Immunotherapy, Tumor Microenvironment, TME, Small Molecule, Treg Cell, MDSC, Immunomodulator, Immune Checkpoint, B-cell Lymphoma, PI3K, PI3 Kinase, HDAC6, p110b, p110d, Solid Tumor, Epithelial Tumor, PD-L1

1. KA2237 is a first-in-class dualPI3K-p110β/δ inhibitor with broad potential to treat hematological and solid tumors, including aggressive β/δ expressing Non-Hodgkin Lymphomas such as Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma, as well as ibrutinib resistant blood cancers.

2. KA2507 is a highly-selective, oral, small molecule HDAC6 inhibitor that has potential in the treatment of liquid tumors such as multiple myeloma and lymphoma, and PD-L1-expressing tumors such as melanoma by acting as a cancer immunotherapeutic.

Description: Clinic stage biopharma company developing oral small molecules for the treatment of solid tumors and haematological cancer. These molecules are in clinical trials at the MD Anderson Cancer Center in Houston, Texas.

Keywords: small molecules, oncology, immune-oncology, tumors, cancer inhibitors, fibrosis, IPF, kidney fibrosis, diabetic nephropathy, antibacterial, multi-drug resistant bacteria, autoimmune Description : Redx is engaged in the discovery and development of novel small molecule therapeutics targeting high unmet needs in oncology, fibrotic and autoimmune diseases.

Keywords: immuno-oncology, oncology, cancer, checkpoint, antibody, oncolytic, oncolytic virus, T-cell, gene therapy, cytokine, delivery, shRNA, immunology Description: Clinical stage Oxford based company focused on immuno-oncology.

Oncolytic viruses and cancer specific immuno-gene-therapy.

psioxus.com

T CELL RECEPTOR-BASED THERAPIES CONTACT: EVA-LOTTA ALLAN, CHIEF BUSINESS OFFICER

www.immunocore.com

Keywords: ImmTAC, T cell receptor, immunology, oncology, HLA targets, malignant cutaneous melanoma, ocular melanoma, glioblastoma Description: Clinical-stage company focused on innovative therapies called ImmTACs, based on its proprietary T cell receptor technology.

1. Porcupine antagonists – preclinical development (oncology and fibrosis) 2. BTK reversible inhibitors – preclinical development (oncology and autoimmune) 3. Pan-RAF antagonists – lead optimization (oncology) 4. MDR gram negative infections – lead optimization 1. Enadenotucirev a systemically available oncolytic virus currently in combination studies with both checkpoint and chemotherapeutic agents 2. NG-347: directs tumor cells to produce membrane bound CD80 and secrete interferon alpha and MIP1 alpha 3. NG-350: directs tumor cells to secrete a full length antibody (mAb identity currently undisclosed) 4. NG-600 series: direct tumor cells to secrete BITes directed against stromal targets such as fibroblasts

1. IMCgp100, completed Phase II for malignant cutaneous and ocular melanoma 2. Additional Assets undisclosed,

6

2017 Partnering Assets

T-CELL THERAPIES Name T-CELL THERAPIES CONTACT: HELEN TAYTON-MARTIN, CHIEF BUSINESS OFFICER

About Keywords: T-cell therapy, Peptide Engineering, Immune System, TCR Therapies

1. T-cell therapy targeting NYESO peptide across multiple cancer types, Phase 1/2 trials

Description: Pre-clinical company focused on proprietary SPEAR (Specific Peptide Engineered Affinity Receptor) T-cell engineering platform.

2. MAGE-A10 T-cell therapy

CONTACT: CHRIS WILLIAMS, DIRECTOR OF BUSINESS DEVELOPMENT

www.autolus.com

3. AFP TCR therapeutic targeted to a peptide associated with hepatocellular carcinoma 4. MAGE-A4 TCR SPEAR T-cell therapy

adaptimmune.com

T-CELL THERAPIES

Assets

Keywords: immuno-oncology, oncology, cancer, T-cell therapies, hematological malignancies, solid tumors Description: Autolus is a leader in Tcell programming and manufacturing technology and has established a development-stage pipeline of products for the treatment of hematological malignancies and solid tumors.

For questions about Autolus assets, please connect with Chris Williams, Director of Business Development at contact@autolus.com

6

2017 Partnering Assets

ANTIBODY THERAPEUTICS MONOCLONAL ANTIBODIES CONTACT: STEVE HOLMES, CHIEF OPERATING OFFICER

Keywords : oncology, immune-oncology, monoclonal antibodies, drug discovery, intestinal bowel disease, scleroderma.

Description: Capella Bioscience uses novel technologies to develop monoclonal antibodies to innovative therapeutic targets in oncology and autoimmune disease.

1. CBS001: Preclinical antibody to a TNFSF member for IBD 2. CBS004: Preclinical antiBDCA-2 antibody for scleroderma 3. CBS007: Tumor specific monoclonal antibody to a checkpoint inhibitor target

capellabioscience.com

ANTIBODY-BASED THERAPIES CONTACT: CHRISTIAN ROHLFF, CHIEF EXECUTIVE OFFICER

www.oxfordbiotherapeutics.com

ANTI-GLYCAN THERAPEUTIC MONOCLONAL ANTIBODIES CONTACT: DR TINA PARSONS, BUSINESS MANAGER

Keywords: oncology, Immunooncology, antibody drug conjugates (ADCs), checkpoint inhibitors, novel antigen targets, solid tumors Description: Clinical-stage biotechnology company developing innovative antibody based therapies for cancer. MEN1112 (OBT357) is an ADCC antibody for AML in phase I testing. MEN1309 (OBT076), an ADC for NHL, triple-negative breast, and other solid tumors, is on track to enter first-in-human trials in mid-2017.

Keywords: immunotherapy, monoclonal antibodies, oncology, solid cancers, pre- clinical, immunogenic cell death, bispecific antibodies, ADC, CAR-T Description: NUTAC develops therapeutic monoclonal antibodies to tumor associated glycans.

www.nottingham.ac.uk/nutac

BISPECIFIC ANTIBODIES CONTACT: DR JANE DANCER, CHIEF BUSINESS OFFICER

1. Proteomics based target discovery platform for identifying novel checkpoint inhibitors and cancer antigens 2. Novel Immuno-oncology programs available for licensing/partnering 3. Pre-clinical ADC assets available for licensing/partnering

1. FG129 pre-clinical monoclonal antibody, recognizes a Sialyl-diLewisa 2. FG88 pre-clinical monoclonal antibody, recognizes Lewisa,c,x 3. FG27 pre-clinical monoclonal antibody 4. Platform and additional early stage pre-clinical assets undisclosed, available for licensing

Keywords: bispecific antibodies, immuno-oncology, Modular Antibody Technology™, Fcab™, mAb²™, cytokines

1. Bispecific antibody programmes in immuno-oncology

Description: Clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer.

2. Modular Antibody Technology platform for strategic collaborations on bispecific antibodies and Fcbased formats

Keywords: basal cell carcinoma, nfP2X7, monoclonal (domain) antibody, peptide vaccine colorectal, breast, prostate, lung, cancer, solid tumor, oncology, cancer, immunooncology Description: Biosceptre is UK based biotech with three products in the clinical pipeline, all targeting a novel oncolog y target - nfP2X7, a form of P2X7 that is expressed only in the tumour microenvironment, and which occurs in a broad range of cancers.

1. BIL03s is our systemic monoclonal (domain) antibody – for solid tumors -entering Phase 1 in Q3 2017

www.f-star.com/

ANTIBODY THERAPEUTICS CONTACT: DANIEL BARTON, DIRECTOR, INVESTOR RELATIONS

www.biosceptre.com

2. BIL06v is our peptide vaccine for solid tumors entering Phase 1 in Q3 2017 3. BIL010t is our topical Antibody treatment for locally advanced Basal Cell Carcinoma (laBCC) Phase 2 in Q3 2017

6

2017 Partnering Assets

ANTIBODY THERAPEUTICS, CONT. MULTISPECIFIC ANTIBODIES CONTACT: DR PEDRO DE NORONHA PISSARRA, CHIEF EXECUTIVE OFFICER

www.biotecnol.com

FUSION ANTIBODIES CONTACT: DR PAUL KERR, MANAGING DIRECTOR

https://www.fusionantibodies.com

ANTIBODY THERAPEUTICS CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR, BUSINESS DEVELOPMENT

Keywords: basal cell carcinoma, nfP2X7, monoclonal (domain) antibody, peptide vaccine Description: Immuno-oncology company developing multispecific Tcell engagers and immune-modulators which locally counter potential blocking signals on T and NK cells.

Keywords: immuno-oncology, monoclonal antibodies, colorectal cancer, breast cancer, lung cancer, prostate cancer, glioblastoma

1. Tb535, pan-cancer T-cell engager for 5T4 expressing tumors, pre-clinical 2. Tb434, pan-cancer T-cell engager against Triple Negative Breast Cancer, pre-clinical 3. Tb232, novel anti-HER2 T-cell engager for mutated and resistant metastatic breast cancers, pre-clinical 4. Various early-stage programs 1. Fsn0503h, an anti-Cathepsin S antibody, against colorectal, breast, prostate, glioblastoma and other cancers (preclinical as monotherapy and in combination)

Description: Antibody humanization company with a preclinical-stage pipeline of antibodies through its Fusion 2. Fsn1006 dual specific IgG1 Therapeutics division. monoclonal antibody which binds AREG and HB-EGF, against colon, breast, lung and other cancers (pre-clinical) Keywords: rat monoclonal antibodies, Her2, Neu, EGFR, CerbB2.

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

1. 1. Monoclonal antibodies against EGFR, thorough preclinical characterization for all, one has completed Phase 1B trials.

2. Monoclonal antibodies against Cerb-B2, extensive preclinical evaluation completed.

www.icr.ac.uk/

MONOCLONAL ANTIBODIES CONTACT: DR STEVE DOWD, DIRECTOR, BUSINESS DEVELOPMENT

kymab.com/

MONOCLONAL ANTIBODY THERAPEUTICS CONTACT: DR SALMAN RAHMAN, CEO

vasgen.co.uk

BICYCLIC PEPTIDES CONTACT: KEVIN LEE, CHIEF EXECUTIVE OFFICER

www.bicycletherapeutics.com

Keywords: monoclonal antibodies, immunology, oncology, drug discovery, mouse models, anemia, chronic pain, dyslipidemia, infectious diseases, Ebola Description: Preclinical- stage company focusing on development of monoclonal antibody drugs in immuno- oncology, immunology, and opportunistic spaces.

Keywords: ADAMs, ADAM15, Metzincin, AMD, cancer, AbIMP, metalloprotease, anti- angiogenesis Description: Pre-clinical-stage company developing first-in- class monoclonal antibody therapies for unmet needs in ophthalmology and oncology medicine.

1. KY1005, Anti-OX40L, for immunology 2. KY1006, Anti-LIGHT, for immunology 3. Numerous other discovery-stage assets for oncology, anemia, chronic pain, Ebola and others 1. First-in-class monoclonal antibody for anti-angiogenesis /anti-tumour therapy in wet AMD, prostate cancer, breast cancer & solid tumours: lead identification.

2. AbIMPÂŽ platform: Targetenabling antibody platform for selective inhibition of intractable metzincin proteases: proof-ofconcept

Keywords: bicyclic peptides, oncology, research collaboration, drug discovery

1. BT1718 bicyclic oncologic agent (pre-clinical)

Description: R&D stage company backed by Atlas Ventures and Novartis Venture funding, among others, exploring the therapeutic possibilities of bicyclic peptides.

2. Research collaboration opportunities to apply proprietary platform to targets from partners

6

2017 Partnering Assets

SMALL MOLECULE INHIBITORS Name ONCOLOGY & WOMEN’S HEALTH CONTACT: DR JOHN NORMANTON, CHIEF EXECUTIVE OFFICER

www.estryx.com

SMALL MOLECULE THERAPEUTICS CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

www.icr.ac.uk

CANCER: GENERAL ONCOLOGY CONTACT: ADAM STOTEN, HEAD OF TECHNOLOGY TRANSFER

https://innovation.ox.ac.uk/

DRUG DEVELOPMENT FOR MULTIPLE MYELOMA CONTACT: JOHN MARCH, CEO

www.icenipharma.com

About

Assets

Keywords: oncology, women’s health, hormone-dependent cancer, Dual Aromatase-Sulfatase Inhibitor, steroid sulfatase inhibition, multi-targeting therapeutic, orally-available, hormone replacement therapy, contraception

1. STX140, an orally active, multi-targeting, orally- available therapeutic for multiple oncology indications, acting as an irreversible steroid sulfatase inhibitor (STSi); a carbonic anhydrase IX (CAIX) inhibitor; a microtubule disruptor; and an angiogenesis inhibitor.

2. Orally active Dual Aromatase-Sulfatase Inhibitor (DASI) for estrogen- dependent tumors 3. DnE2MATE for oral contraception & HRT

Description: A new drug development company focused on the design and development of small molecule therapeutics in oncology and women’s health.

Keywords: novel small molecule inhibitors, enzyme inhibitors, folate receptor, phase 1, hypoxic tumors, AML, colorectal cancer, metastasis, invasion, lung cancer, hepatoma, head and neck tumors, breast cancer, ovarian cancer, colorectal cancer.

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

Keywords: biomarker, Ewings sarcoma, oncology, Therapeutic, STSi, CAIX, microtubule, angiogenesis, aromatase, 17ßestradiol, DASI Description: Isis Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.

Keywords: Drug development, Multiple Myeloma, Cilengitide-based therapy Description: Iceni Pharmaceuticals develops cancer therapies, specializing in repurposing and reformulating existing drugs for new indications.

1. BTG945 (ONX-0801, BGC945): First-inclass α-folate receptor targeted ovarian cancer therapeutic and companion diagnostic; phase 1 results presented at ASCO 2017 (Abstract #2503).

2. FLT3/AURORA: potent and orally bioavailable clinic-ready dual FLT3/Aurora kinase inhibitor for AML (clinic-ready).

3. LOX: for the treatment of breast, ovarian and colorectal cancer, inhibitors should prevent tumour progression and metastases (late lead optimization).

4. GDEPT: Gene-directed enzyme pro- drug therapy, for treatment of lung, colorectal, head and neck tumors, as well as hepatoma (pre-clinical).

1. A novel and specific biomarker on the cell surface of Ewing’s Sarcoma tumors that can be used as a diagnostic or therapeutic target.

2. STX140 - an orally active multi-targeting drug for multiple oncology indications, acting as an irreversible steroid sulfatase inhibitor (STSi); a carbonic anhydrase IX (CAIX) inhibitor; a microtubule disruptor; and an angiogenesis inhibitor.

3. Orally active Dual Aromatase- Sulfatase inhibitors (DASI) for treatment of estrogendependent cancers.

1. Cilengitide-based therapy for multiple myeloma 2. Novel formulation and delivery technologies, currently at pre-clinical in vivo optimization 3. Clengitide in combination with proteasome inhibitors for the treatment of breast cancer

6

2017 Partnering Assets

SMALL MOLECULE INHIBITORS, CONT.

CONTACT: DR TIM MITCHELL, CHIEF EXECUTIVE OFFICER

Keywords: oncology, lung cancer, pancreatic cancer, AML, lymphoma, neuroblastoma, JAK family, psoriasis, rheumatoid arthritis, RA, multiple sclerosis, MS, lupus, inflammatory bowel disease, IBD

www.sareum.com

Description: Drug discovery and development company, with a focus on targeted small molecule therapeutics for cancer and autoimmune diseases.

ONCOLOGY & AUTOIMMUNE

UBIQUITIN PATHWAY MODULATION CONTACT: PAUL WALLACE, CHIEF BUSINESS OFFICER

Keywords: Ubiquitin, small molecule drugs, targeting de-ubiquitylating enzymes (DUBs), novel therapeutics Description: Drug discovery and development company, with a focus on targeted small molecule therapeutics for deubiquitylating enzymes.

1. Aurora+FLT3 kinases inhibitor, targeting AML and ALL (preclinical) 2. TYK2 kinase inhibitor, targeting T-ALL (lead opt)

1. USP7 – DUB with immuneoncology link and an established anti-cancer target 2. Inhibitors of selected DUBs involved in DDR 3. Additional DUB oncology targets

www.missiontherapeutics.com

BIOMARKER OPPORTUNITIES CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

www.icr.ac.uk

Keywords: MPS1, ATR, biomarker, stratification, diagnostic, SMARCB1deficient, Sarcoma, PDGFRα, FGFR1, resistance.

1. MPS1 inhibitor Resistance Diagnostic: based on point mutations that confer resistance against multiple inhibitors.

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

2. ATR Inhibitor Sensitivity Diagnostic; method of identifying cancer patients likely to be responsive to treatment with an ATR inhibitor.

3. Treatment of SMARCB1deficient Sarcomas: basis for dual targeting with inhibitors towards PDGFRα and FGFR1.

6

2017 Partnering Assets

GENE THERAPY Name GENE SILENCING CONTACT: MARK TREHARNE, CORPORATE DEVELOPMENT MANAGER

About Keywords: genetic medicine, oncology, GeneICE, Bcl-2 inhibition, prostate cancer, breast cancer, ovarian cancer, endometriosis, cancer screening, lung cancer Description: Clinical-stage company developing cancer therapies and associated biomarkers, with sub-focuses in neurology and inflammatory disease.

www.valirx.com

RNA-BASED THERAPEUTICS CONTACT: LUCIO IANNONE, RESEARCH & DEVELOPMENT MANAGER

Keywords: genetic medicine, pancreatic cancer, head and neck cancer, lung disease, pulmonary hypertension, RNA interference, gene silencing, messenger RNA, RNAi, mRNA

www.silence-therapeutics.com/

Description: Clinical-stage company which utilizes RNA interference (RNAi) and mRNA technology to develop therapies which ‘silence’ disease-causing gene expression.

Assets VAL 101 GeneICE Bcl-2 inhibitor, against prostate, ovarian, and pancreatic cancers VAL 201, against prostate cancer (with potential in breast and ovarian cancers, endometriosis), Phase I VAL 401, against lung cancer, pre-clinical 1. Atu027, against pancreatic cancer, Phase II 2. Atu027, against head and neck cancer, Phase I 3. Atu111, against lung indications,

LipTideTM – a new, custombuilt vector to deliver your gene therapy

Keywords: gene therapy, siRNA, gene editing, DNA, RNA vaccine, delivery, viral, liptide, liposome, crispr, CAS9, saRNA, mRNA, DNA, plasmid

1. LipTideTM can be modified to

CONTACT: DR ALAN WALKER, DIRECTOR BUSINESS DEVELOPMENT

Description: The greatest challenge

2. LipTideTM has been

www.LipTide.com

facing researchers has been the inability to deliver nucleic acids into target cells with efficiency, specificity and minimal side effects and this is holding back the true potential of gene therapy.

Nanogenics is proud to introduce LipTideTM; an exciting custom-built delivery vehicle for all gene therapy.

Every aspect of LipTideTM can be modified to target different cell types and deliver different payloads. Nanogenics are looking to out-licence LipTideTM to help translate your gene therapy into potential clinical programs.

target different cell types and does not accumulate in the liver. successfully administered in vivo by nebulisation, systemic delivery (i.v.) and by convectionenhanced delivery to the brain.

3. LipTideTM delivers for all nucleic acid payloads including siRNA, saRNA, mRNA, DNA and even artificial chromosomes.

6

2017 Partnering Assets

DRUG DISCOVERY IN RARE AND ORPHAN INDICATIONS Name GLIOBLASTOMA CONTACT: DR ANDY MORLEY, CHIEF SCIENTIFIC OFFICER

www.opalonc.com/

ORPHAN ONCOLOGY

About Keywords: oncology, Glioblastoma, research collaboration, drug discovery, small molecule, brain penetrant

Assets 1. Proprietary novel approach for the treatment of Glioblastoma Multiforme and other cancer indications. Pre-clinical.

Description: Opal Oncology seek out commercially viable anti-cancer therapies in high-impact orphan cancer indications which have been failed by existing therapies.

Keywords: orphan drugs, oncology, endometrial cancer, triple negative breast cancer, TNBC, sodium cridanimod, anemia, erythropoietin, EPO, PSA-EPO, PolyXen™ .

1. Sodium cridanimod in Phase II for endometrial cancer and preclinical stage for triple negative breast cancer.

Description: Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics.

2. Polysialylated EPO, in Phase II for anemia in predialysis CKD patients.

Keywords: Oncology, CNS, Rare Diseases, Alzheimer disease, checkpoint inhibitors, immunotherapy, late stage cancer

1. Immune-oncology platform based on the secretome in selected solid tumors

Description: Drug discovery engine in Europe focused on the development of early stage assets from academic and non academic assets into therapeutic opportunities with a solid proof of concept ready for industrial partnering

2. anticancer platform combining biomimetic molecules with innovative cytotoxic payloads in late stage cancers

SMALL MOLECULE ORPHAN DRUGS

Keywords: rare disease, orphan indication, drug candidate, Fragile X syndrome

CONTACT: BOB BOYLE, CHIEF EXECUTIVE OFFICER

Description: Drug discovery company dedicated to the development of novel drug candidates in areas of high unmet medical need.

1. SOL784 a candidate drug in development for the treatment of Fragile X Syndrome a rare disease and the largest single genetic cause of autism.

CONTACT: JEFFREY EISENBERG, CHIEF OPERATING OFFICER

www.xeneticbio.com

ONCOLOGY, CNS & RARE DISEASES CONTACT: EDOARDO NEGRONI, CHIEF EXECUTIVE OFFICER

www.inorgen.com/

3. drug repurposing in a panel of pediatric rare diseases

www.sentineloncology.com

NOVEL DRUG TARGETS IN ONCOLOGY CONTACT: CHRIS TORRANCE, CEO

www.phoremost.com/

Keywords: Phenotypic drug discovery, PROTEIN-interference technology, firstin-class targets, collaborative R&D, outlicensing portfolio Description: PhoreMost is using a proprietary druggable target identification platform called ‘Protein Interference’ (PROTEINi®) to systematically provide first-in-class drug discovery programs for out-licensing to Pharma.

1. R&D collaborations Pre-clinical stage asset for oncology (AML and mutant KRAS cancers).

6

2017 Partnering Assets

CLINICAL ONCOLOGY: MEDICAL DEVICES AND TECH Name SOCIAL NETWORK FOR HEALTH CONTACT: PHIL GOLZ, EVP, CHIEF REVENUE OFFICER

https://healthunlocked.com

REMOTE PATIENT MONITORING CONTACT: MARCO FIORI

www.medopad.com

SELF-MANAGEMENT TECHNOLOGY CONTACT: MATTHEW GOODMAN, MEDICAL DIRECTOR

About Keywords: Social Networking, Patient Engagement, Online Forum, Clinical trial recruitment, clinical research, online communities, peer to peer support, expert patients, patient centered outcomes research

Assets HealthUnlocked is a social network available on desktop and iphone app

Description: HealthUnlocked is a social network for health. It connects people with the same health and wellbeing conditions within online communities where they find peer to peer and expert support, information and self-management help. They partner with hundreds of patient advocacy organizations within these communities. They additionally offer a wide range of unique solutions to organizations and businesses, specializing in access to an active health focused audience.

Keywords: Remote Patient Monitoring, Wearable Tech integration, Mobile Devices, Patient Engagement, Healthcare Data management and analytics Description: Medopad helps doctors better monitor their patients in and outside of the hospital. Medopad is used by NHS London hospitals, BMI Healthcare, University Medicine Goettingen, and HCA – The Harley Street Clinic. Medopad recently signed its first pharmaceutical contract and is in the process of deploying its Patient Monitoring solutions for a range of conditions.

Keywords: Digital Therapeutics, Technology Enabled Care Services, Long-Term Conditions, Diabetes, Patient Self-Management, Patient Engagement, Mobile App Description: Mapmyhealth designs Digital Therapeutics for providers and patients alike. They produce specialized platforms for diabetes, weight loss and cancer.

1. Medopad Patient Monitoring, a solution offering remote patient monitoring and doctor/patient communication for multiple medical conditions 2. Medopad Enterprise, a powerful mobile solution that is integrated into existing hospital systems

SurvivorMap – ensuring those living with, and beyond cancer, get the care and support they need to lead as healthy and active life as possible

http://www.mapmyhealth.co.uk

WEARABLE SELFMONITORING CONTACT: VICTORIA PERRY, BUSINESS MANAGER

www.cohesionmedical.com

Keywords: Unified Health Eco-System, Wearable Sensor Technology, Patient Self-Management Mobile Apps, Shared Care Environments, Electronic Patient Records, Clinical Workflow Software, Data Interface Integration, Disease Registries, Real-Time Data Analytics, Life-Long Health, Long Term Conditions, Cancer, Surgery, General Medicine, Specialist Clinics Description: Cohesion Medical is an award-winning leading-edge provider of Connected Digital Health solutions. Our solutions connect stakeholders in new and more effective ways within a unifying health ecosystem. With our connected technology, we create shared bridges across health and social care services to make effective transformational change possible.

1. Patient Self-Management Mobile Application for Long Term Conditions 2. Cloud-Based Shared Care Environment for Virtual Clinics and Remote Monitoring 3. Cloud or On-Site Cohesion Clinical Collaboration Software Suite for Optimised Clinical and Research Workflows.

4. Digital Platform for RealTime Health Data Analytics

6

MEDICAL DEVICE OPPORTUNITIES CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

2017 Partnering Assets

Keywords: rapid and accurate slicing of tissue samples, co- alignment, tissue imaging, tissue arrays, high sample density, cervix imaging, microscopic imaging, digital imaging, photoacoustic imaging, ultrasound imaging.

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

www.icr.ac.uk

1. Device for tissue processing: prototypes sold to academic researchers.

2. Endocovitary coil for improved 3T-MR diagnostic imaging of the cervix (proof of concept, clinical ongoing).

3. Polyscope: solution for visualization of digital microscopic samples (preproduction prototype in development).

4. ARF-LOVIT system: for reducing clutter in medical photoacoustic, ultrasound and other imaging using acoustic radiation force-based localised vibration tagging.